Organicell Regenerative Medicine, Inc. responds to recent promotional activities as requested by OTC markets
Davie, Florida – November 21, 2022 – Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) (“Organicell” or the “Company“) was requested by OTC Markets Group, Inc. (“OTC markets“) to release this statement on promotional activity regarding its common stock.
On November 17, 2022, OTC Markets notified the Company of the distribution of three promotional email newsletters (the “Newsletters”), each dated November 15, 2022. The three email newsletters were published by Wall Street Alerts , Epic Stocks Picks, and Green Leaf Pot Stocks, respectively, and discussed, among other things, the company, its current and planned products, the potential market for its products, and the potential for stock price upside. The publications also contained a summary of several recent press releases issued by the Company. OTC Markets has provided the Company with the Newsletters for reference. The Company was not aware of the Newsletters prior to receiving them from OTC Markets.
The Company takes its investor relations practices seriously, including its obligations to timely and accurately disclose material information that can reasonably be expected to have a material effect on the price of the market or the value of its securities. Specific statements in newsletters regarding company stock and benefits are highly speculative and should be carefully evaluated based on the company’s latest filings on sec.gov.
The Company has been a fully reporting company, filing periodic reports under Section 13 of the Securities Exchange Act of 1934, since June 2013 and its common stock has been listed on the OTCQB since November 9, 2021.
As part of the Company’s efforts to increase awareness of its brand and business with the investment community and stock markets, in August 2022, the Company engaged TraDigital Marketing Group (“TraDigital“) to provide investor and public relations services designed to assist Organicell in achieving its objective of raising the Company’s profile in the investment community and securities markets, although, among other actions, by making IPOs to investment banks and brokerage firms, lawyers, consultants, public relations firms, investor relations firms, brand awareness firms and digital marketing companies.
From August to November 2022, TraDigital and its affiliate company worked with several companies to increase awareness of the company. In addition, as is required of a public company, Organicell issued a number of press releases during this period reporting significant developments and achievements, most of which were also filed under the guise of the reports. current on Form 8-K with the Securities and Exchange Commission. . These press releases have also been included on the Company’s page on the OTC Markets website.
To assist TraDigital in its efforts on behalf of the Company, Organicell has provided TraDigital with copies of its periodic reports filed with the Securities and Exchange Commission, its press releases and an investor presentation, which has been filed with the SEC. under the name of “7.01 Disclosure of FD Rulesin a current report on Form 8-K on October 12, 2022.
As part of its engagement, TraDigital and its affiliate have engaged one or more outside companies to provide marketing services.
To the knowledge of the Company, each of Wall Street Alerts, Epic Stock Picks and Green Leaf Pot Stocks is a third-party marketing and advertising company that provides content distribution and advertising services. Epic Stock Picks and Green Leaf Pot Stocks state that their newsletters are owned and operated by Link Media.
Each of the newsletters presented factual statements about the company, its current and planned business and industry, apparently taken from the company’s filings with the SEC. Neither the Company nor TraDigital consulted or exercised editorial control over the materials, and did not review the materials for factual accuracy or even view them prior to their release. Although the Company does not believe that the factual statements in the newsletters based on SEC filings and Organicell press releases were false or misleading, both newsletters included information and language that would statements of fact contained in the Company’s filings and press releases with the SEC. As stated, neither the Company nor TraDigital had any control over the content of the promotional material.
The Company has no knowledge or opinion as to whether the Newsletters have affected trading activity, however, the Company acknowledges that the trading volume on November 15, 2022, the date of publication of the Newsletters, was significantly higher than previous daily volume levels, and that the trading price has risen on that date compared to that of previous trading days.
As noted, neither the Company nor its officers or directors had any involvement in the creation of the information contained in the email newsletters, except for information extracted from the Company’s filings with the SEC and press releases. press releases, which have been prepared and published by the Company.
After due investigation, the Company confirms that it is not aware of any of its controlling persons, officers, directors or any shareholder holding 10% or more of the Company’s securities, who may have, directly or indirectly, been involved in any way in the creation or distribution of promotional materials relating to the Company and its securities, other than the preparation of the Company’s SEC filings and press releases related press releases, the substance of which has been included in the referenced newsletters. As noted above, TraDigital and its affiliate were involved in engaging the external marketing company which engaged Wall Street Alerts, Epic Stock Picks and Green Leaf Pot Stocks, and advanced funds to the marketing company external for partial payment of marketing services. However, neither TraDigital nor its affiliate was involved in the creation or distribution of the email newsletters or any other promotional material.
After due investigation with management, directors, controlling persons and any third party service providers, the Company can confirm that neither the Company, its controlling persons, officers, directors, majority shareholders or any third-party service provider have sold or purchased the securities of the Company within the past 90 days, except for transactions that have been reported in the Company’s filings with the SEC.
Other than as stated above, the Company has not engaged any third party vendor to provide investor relations services, public relations services, marketing or other related services, including the promotion of the Company or its securities over the last twelve months.
Since August 2022, the Company has not issued any ordinary shares or convertible instruments allowing conversion into equity securities at prices representing a discount to the market rate prevailing at the time of issue.
About Organicell Regenerative Medicines, Inc.
Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company primarily focused on the development of innovative biological therapies for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain naturally occurring exosomes, hyaluronic acid and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Law“), the Securities Exchange Act of 1934, as amended (the “Exchange Law“), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks and uncertainties, and such expectations may prove to be incorrect. We remember that actual results could vary materially due to known and unknown risks and uncertainties, including, but not limited to: potential problems with our financial condition, competition, ability to retain key personnel, the safety, efficacy and acceptance of products, the commercial success of any new products or technologies, the success of clinical programs, the ability to retain customers c damages, our inability to expand sales and distribution channels, laws or regulations affecting our operations, including product pricing, reimbursement or access, ability to protect our patents and other intellectual property rights both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports which are filed with the SEC and available on the the SEC (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. The specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and expressly disclaims any obligation to update the information contained in this press release.
Investor Relations and Media Relations
Organicell Investor Relations
1-888-963-7881 ext. 701
#Organicell #Regenerative #Medicine #Responds #Promotional #Activities #Demand #OTC #Markets #Form #MarketScreener